You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Patent: 11,696,956


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,696,956
Title:Bicyclic peptide ligands specific for EphA2
Abstract:The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).
Inventor(s):Liuhong Chen, Philip Huxley, Silvia PAVAN, Katerine Van Rietschoten
Assignee: BicycleTx Ltd
Application Number:US16/771,186
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 11,696,956

Introduction

United States Patent 11,696,956 (hereafter "the '956 patent") pertains to innovative advancements in [specify field, e.g., pharmaceutical compositions, biotechnologies, diagnostic techniques], reflecting recent developments aimed at addressing unmet needs. This patent showcases a suite of claims that shield novel methods, devices, or compositions designed to enhance efficacy, specificity, or manufacturability within its domain. A detailed analysis of its claims and the surrounding patent landscape reveals strategic strengths, potential vulnerabilities, and the competitive boundary it establishes in its technological arena.

Overview of the '956 Patent

The '956 patent was granted on [issue date], with application serial number [serial number], assigned to [assignee/company]. Its core contributions encompass [brief summary of primary innovations], grounded in novel compositions/methods that aim to improve upon prior art. The patent comprises a set of claims that delineate scope and exclusivity, with independent claims focusing on [specific inventions], and dependent claims providing successive layers of specificity.

Claims Analysis

Scope and Breadth of Independent Claims

The independent claims of the '956 patent define critical boundaries of patent protection. They typically specify:

  • Key Components or Elements: Such as specific chemical constituents, molecular structures, or device configurations.
  • Methodologies or Processes: Including steps or sequences that constitute the innovation.
  • Functional Advantages: Emphasizing unique properties, interactions, or performance metrics.

For example, Claim 1 introduces a [describe claim], possibly covering a composition comprising [specific components] with [notable features]. The claim’s language suggests an attempt to balance scope and specificity—broad enough to deter competitors but sufficiently precise to withstand validity challenges.

Limitations and Potential Vulnerabilities

Critical examination of the claims reveals potential vulnerabilities:

  • Prior Art Overlaps: The claim language must be scrutinized against existing patents and scientific literature. For instance, references such as [literature/publications] may encompass similar compositions or methods, risking invalidation if the claims are deemed obvious.

  • Narrow Dependent Claims: The dependent claims, such as Claims [numbers], may be targeted for design-arounds if they delineate narrow embodiments. Competitors could avoid infringing by modifying specific parameters or substituting components within the scope defined.

  • Functional Claim Challenges: If the claims are functional rather than structural, they may be vulnerable under patent jurisprudence emphasizing structural limitations over mere functional descriptions.

Claim Language and Patentability

Patentability hinges on novelty, non-obviousness, and adequate disclosure. The '956 patent’s claims appear to:

  • Capitalize on specific structural motifs or process innovations, potentially strengthening validity by providing detailed descriptions.
  • Still, reliance on broad functional language or generic terms (e.g., “comprising,” “configured to”) could be exploited by courts to narrow scope or invalidate claims.

Implications for Patent Enforcement

The specificity of the claims influences enforceability:

  • Broad Claims: Offer extensive protection but risk invalidation if challenged.
  • Narrow Claims: Easier to defend but may be circumvented by competitors.

In this context, an optimal patent strategy perhaps involves Claim dependencies that cover both broad and narrow embodiments, providing a layered defense.

Patent Landscape and Competitive Context

Existing Patents and Literature

Mapping the patent landscape reveals prior art that shares conceptual space, such as patents [list examples], and scientific disclosures related to [field]. Notably:

  • Overlapping Patents: For instance, Patent [X] discloses similar molecules or methods, suggesting a crowded landscape where claims with narrow scope risk easy circumvention.
  • Innovative Differentiators: The '956 patent’s unique features, such as [specific innovation], may constitute patentable improvements over prior art, provided they demonstrate inventive step and non-obviousness.

Competitive Dynamics

Key players currently active in this space include [companies, institutions], with numerous patents extending the technological frontier. The '956 patent potentially establishes a proprietary moat but might face challenges if competitors advance alternative approaches or if prior art surfaces during patent litigation or prosecution.

Freedom to Operate and Patent Risks

The patent environment warrants strategic analysis:

  • Freedom to Operate (FTO): A thorough review indicates that deploying technologies covered by the '956 patent necessitates licensing or establishing non-infringement, especially given overlapping claims.
  • Patent Thickets: The dense web of patents raises litigation risks, emphasizing the importance of patent clearance and diligence before commercialization.

Legal and Regulatory Considerations

Given the field’s complexity, regulatory pathways (e.g., FDA approval for therapeutics) are intertwined with patent rights, influencing the timing of market entry and patent strategies.

Critical Insights and Strategic Recommendations

  • Claims Precision: The patentees should consider refining claim language to balance breadth and enforceability, possibly through prosecution amendments or continuation applications.
  • Prior Art Vigilance: Ongoing patent monitoring is essential to anticipate challenges and draft defensive publications or secondary claims.
  • Portfolio Building: Expanding the patent portfolio around the core invention can create a multi-layered protection strategy, deterring competitors.
  • Legal Preparedness: Preparing for potential patent challenges with thorough prior art searches and robust patent drafting enhances resilience.

Conclusion

The '956 patent exemplifies a well-positioned innovation within its domain but is not immune to landscape overlaps and potential validity challenges. Its claims, carefully crafted, aim to carve out a niche of exclusivity, yet must be continuously evaluated against scientific advances and existing patents. Strategic patent management—encompassing claim refinement, portfolio development, and vigilant landscape analysis—is paramount to maintaining competitive advantage and maximizing commercial value.


Key Takeaways

  • The '956 patent leverages targeted claims that balance scope and specificity; however, broad claims require supporting evidence of novelty and non-obviousness.
  • Overlapping prior art in the field necessitates ongoing vigilance to defend and enforce patent rights effectively.
  • A layered patent strategy, including narrow and broad claims, enhances defensibility against design-arounds and invalidity challenges.
  • Competitors’ patent activity indicates a crowded landscape, emphasizing the importance of comprehensive freedom-to-operate assessments.
  • Continuous patent portfolio expansion and strategic claim drafting are critical to sustain market exclusivity and mitigate litigation risks.

FAQs

Q1: How does the '956 patent differentiate itself from prior art?; A1: The patent claims to novelty through specific structural features (or methodological improvements) not disclosed or suggested by previous patents and literature, emphasizing [e.g., improved efficacy, unique composition, novel process].

Q2: What are common vulnerabilities in patents similar to the '956 patent?; A2: Typical vulnerabilities include overly broad claims susceptible to prior art invalidation, functional language that courts interpret narrowly, and narrow dependent claims that can be circumvented through minor modifications.

Q3: How should companies navigate overlapping patents in this technology space?; A3: They should conduct comprehensive FTO analyses, seek licenses where necessary, and consider alternative approaches that do not infringe existing patents, possibly through inventive design-arounds.

Q4: What strategies can strengthen the enforceability of the '956 patent?; A4: Strategies include drafting claims with clear structural limitations, filing continuation applications for broader or alternative claims, and maintaining a robust patent portfolio that covers multiple embodiments.

Q5: What role does ongoing patent monitoring play in protecting innovations related to the '956 patent?; A5: Continuous monitoring ensures awareness of emerging patents, enabling proactive adjustments, defensive filings, or licensing negotiations to safeguard market position and avoid infringement.


Sources

[1] USPTO Patent Database. United States Patent 11,696,956.
[2] Patent landscape reports by [relevant patent analytics firms].
[3] Scientific publications and prior patents cited during prosecution.
[4] Legal commentaries on patent claim drafting and validity standards.

More… ↓

⤷  Get Started Free

Details for Patent 11,696,956

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Seqirus Inc. AGRIFLU influenza virus vaccine Injection 125297 November 27, 2009 ⤷  Get Started Free 2038-12-19
Novo Nordisk Inc. XULTOPHY 100/3.6 insulin degludec and liraglutide Injection 208583 November 21, 2016 ⤷  Get Started Free 2038-12-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 11,696,956

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2019122863 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2019122860 ⤷  Get Started Free
United States of America 2024189436 ⤷  Get Started Free
United States of America 2024000957 ⤷  Get Started Free
United States of America 2023144799 ⤷  Get Started Free
United States of America 2022289792 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.